MCID: PDT019
MIFTS: 26

Pediatric Fibrosarcoma

Categories: Cancer diseases

Aliases & Classifications for Pediatric Fibrosarcoma

MalaCards integrated aliases for Pediatric Fibrosarcoma:

Name: Pediatric Fibrosarcoma 12 14
Childhood Fibrosarcoma 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3520
NCIt 46 C8088
UMLS 69 C0279981

Summaries for Pediatric Fibrosarcoma

MalaCards based summary : Pediatric Fibrosarcoma, also known as childhood fibrosarcoma, is related to adult mesoblastic nephroma and cellular congenital mesoblastic nephroma. An important gene associated with Pediatric Fibrosarcoma is NTRK3 (Neurotrophic Receptor Tyrosine Kinase 3), and among its related pathways/superpathways are Brain-Derived Neurotrophic Factor (BDNF) signaling pathway and Neurotrophic factor-mediated Trk receptor signaling. The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include bone, liver and bone marrow, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Pediatric Fibrosarcoma

Graphical network of the top 20 diseases related to Pediatric Fibrosarcoma:



Diseases related to Pediatric Fibrosarcoma

Symptoms & Phenotypes for Pediatric Fibrosarcoma

GenomeRNAi Phenotypes related to Pediatric Fibrosarcoma according to GeneCards Suite gene sharing:

25 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-108 9.58 NTF3 TPM3
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.58 TPM3
3 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.58 NTF3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.58 NTF3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.58 TPM3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.58 TPM3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.58 NTF3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.58 TPM3
9 Increased shRNA abundance (Z-score > 2) GR00366-A-182 9.58 TPM3
10 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.58 NTF3
11 Increased shRNA abundance (Z-score > 2) GR00366-A-24 9.58 TPM3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.58 TPM3
13 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.58 TPM3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.58 NTF3
15 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.58 TPM3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.58 NTF3
17 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.58 TPM3

MGI Mouse Phenotypes related to Pediatric Fibrosarcoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 no phenotypic analysis MP:0003012 8.92 ETV6 NTRK3 TPM3 UBE2I

Drugs & Therapeutics for Pediatric Fibrosarcoma

Drugs for Pediatric Fibrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
3
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
4
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
6
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
7
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
8
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
9
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
10
Cyproheptadine Approved Phase 3 129-03-3 2913
11
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
12
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
13 Alkylating Agents Phase 3,Phase 1,Phase 2
14 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
15 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
16 Isophosphamide mustard Phase 3,Phase 2 0
17 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
18 Anti-Infective Agents Phase 3,Phase 2
19 Antimitotic Agents Phase 3,Phase 1,Phase 2
20 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
21 Antirheumatic Agents Phase 3,Phase 2,Phase 1
22 Etoposide phosphate Phase 3,Phase 2
23 Immunosuppressive Agents Phase 3,Phase 2
24 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
25 Anti-Allergic Agents Phase 3
26 Antipruritics Phase 3
27 Dermatologic Agents Phase 3
28 Gastrointestinal Agents Phase 3
29 Histamine Antagonists Phase 3
30 Histamine H1 Antagonists Phase 3
31
Histamine Phosphate Phase 3 51-74-1 65513
32 Neurotransmitter Agents Phase 3
33
Serotonin Phase 3 50-67-9 5202
34 Serotonin Agents Phase 3
35 Serotonin Antagonists Phase 3
36
Estramustine Approved, Investigational Phase 1, Phase 2 2998-57-4 259331 18140
37
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
38
Vinblastine Approved Phase 1, Phase 2 865-21-4 241903 13342
39
Vinorelbine Approved, Investigational Phase 1, Phase 2 71486-22-1 44424639 60780
40
Lenograstim Approved, Investigational Phase 2 135968-09-1
41 Thiotepa Approved, Investigational Phase 2 52-24-4 5453
42
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
43
Everolimus Approved Phase 2 159351-69-6 6442177
44
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
45
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
46
Mesna Approved, Investigational Phase 2 3375-50-6 598
47 Albumin-Bound Paclitaxel Phase 1, Phase 2
48 Antineoplastic Agents, Hormonal Phase 1, Phase 2
49 Imatinib Mesylate Phase 2 123596
50 Protein Kinase Inhibitors Phase 2

Interventional clinical trials:

(show all 15)

# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
4 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
5 Combination Chemotherapy in Treating Patients With Advanced Cancer Completed NCT00004105 Phase 1, Phase 2 estramustine phosphate sodium;paclitaxel;vinorelbine ditartrate
6 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
7 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
8 Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Completed NCT00002515 Phase 2 carboplatin;thiotepa;topotecan hydrochloride
9 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Active, not recruiting NCT01614795 Phase 2 temsirolimus
10 Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma Terminated NCT00072280 Phase 2 cyclophosphamide;etoposide;ifosfamide;vincristine sulfate
11 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride
12 Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery Completed NCT00450736 Phase 1 celecoxib
13 Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas Completed NCT01567046
14 Genetic Study of Children With Soft Tissue Sarcoma or Rhabdomyosarcoma Completed NCT00003793
15 Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma Withdrawn NCT00334984 glutamine

Search NIH Clinical Center for Pediatric Fibrosarcoma

Genetic Tests for Pediatric Fibrosarcoma

Anatomical Context for Pediatric Fibrosarcoma

MalaCards organs/tissues related to Pediatric Fibrosarcoma:

38
Bone, Liver, Bone Marrow

Publications for Pediatric Fibrosarcoma

Variations for Pediatric Fibrosarcoma

Expression for Pediatric Fibrosarcoma

Search GEO for disease gene expression data for Pediatric Fibrosarcoma.

Pathways for Pediatric Fibrosarcoma

Pathways related to Pediatric Fibrosarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.11 NTF3 NTRK3
2
Show member pathways
10.41 NTF3 NTRK3

GO Terms for Pediatric Fibrosarcoma

Biological processes related to Pediatric Fibrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.37 NTF3 NTRK3
2 activation of MAPK activity GO:0000187 9.32 NTF3 NTRK3
3 activation of GTPase activity GO:0090630 9.26 NTF3 NTRK3
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.16 NTF3 NTRK3
5 activation of protein kinase B activity GO:0032148 8.96 NTF3 NTRK3
6 positive regulation of actin cytoskeleton reorganization GO:2000251 8.62 NTF3 NTRK3

Sources for Pediatric Fibrosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....